The KRT8 Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated to disrupt the endogenous KRT8 gene in the human Ca Ski cervical carcinoma line. This loss-of-function model provides a powerful tool for dissecting the biological roles of keratin 8 (K8), a type II intermediate filament protein that forms obligate heteropolymers with keratin 18 (KRT18). By eliminating KRT8 expression, researchers can systematically investigate how disruption of the keratin intermediate filament network impacts epithelial integrity, mechanical resilience, intracellular signaling, and apoptotic regulation. The polyclonal nature of the population reflects a heterogeneous mix of edited alleles, enabling robust interrogation of gene function without the clonal selection artifacts often associated with monoclonal cell lines.
The host Ca Ski cell line is derived from an epidermoid carcinoma of the cervix and harbors integrated human papillomavirus type 16 (HPV-16) DNA. These cells exhibit characteristic epithelial morphology and serve as a well-established model for HPV-16-mediated oncogenesis. Their tumorigenic background, combined with the presence of viral oncoproteins E6 and E7, makes Ca Ski cells particularly suitable for studying the interplay between keratin dynamics, viral transformation, and cancer progression. The knockout model thus provides a contextually relevant system for examining how KRT8 loss modifies oncogenic signaling, stress responses, and the mechanical properties of cervical cancer cells.
Keratin 8 functions as an essential structural and regulatory component of epithelial cells. It assembles with KRT18 into heteropolymeric intermediate filaments that anchor at desmosomes and hemidesmosomes through interactions with plectin and desmoplakin, thereby maintaining tissue cohesion. KRT8 is regulated by a complex signaling network: upstream, epidermal growth factor (EGF) and transforming growth factor-beta (TGF-??) activate kinases such as AKT, ERK, protein kinase C (PKC), and ROCK, which phosphorylate K8 at specific residues, modulating filament solubility and organization. Transcription factors p63 and AP-1, along with retinoic acid, control its expression. Downstream, KRT8 influences focal adhesion dynamics, cell migration, AKT and ERK signaling outputs, and Fas receptor-mediated apoptosis. It also interacts with 14-3-3 proteins, which sequester phosphorylated keratins and regulate their distribution. Key pathway components including ERK1/2, AKT, ROCK, p38, and JNK are integral to its function. Knockout of KRT8 therefore disrupts not only the physical scaffold but also the signaling hubs organized by these filaments.
In the Ca Ski HPV-positive context, loss of KRT8 is predicted to alter cell morphology, reduce mechanical stability, and perturb signaling pathways critical for cervical cancer progression. The disruption of keratin networks may impact cell adhesion and migration, potentially influencing epithelial-to-mesenchymal transition (EMT) programs that are often activated during metastasis. Moreover, since KRT8 participates in apoptosis regulation via Fas receptor interactions and AKT signaling, its knockout may modulate sensitivity to chemotherapeutic agents such as cisplatin. This model thus offers a unique platform to study how viral oncoproteins and keratin filament integrity jointly influence tumor cell behavior and drug resistance.
This knockout cell population supports a wide range of experimental investigations, including analysis of keratin-dependent cell migration and invasion, EMT, apoptosis, and drug sensitivity. Representative assays include western blotting for KRT8 and phospho-keratins, immunofluorescence staining to visualize intermediate filament networks, transwell migration and invasion assays, flow cytometry-based apoptosis detection, and co-immunoprecipitation with KRT18. Phospho-signaling analysis using antibodies against phospho-AKT and phospho-ERK can delineate pathway alterations. Researchers can also perform cisplatin dose-response studies to evaluate changes in drug susceptibility. For further technical specifications, validation data, or custom inquiries, please contact Ascent Research.
